<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Imaging</journal-id><journal-title-group><journal-title>Cancer Imaging</journal-title></journal-title-group><issn pub-type="ppub">1740-5025</issn><issn pub-type="epub">1470-7330</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4601618</article-id><article-id pub-id-type="publisher-id">1470-7330-15-S1-P9</article-id><article-id pub-id-type="doi">10.1186/1470-7330-15-S1-P9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Oxygen-enhanced MRI can accurately identify, quantify and map tumour hypoxia in preclinical models</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>O'Connor</surname><given-names>JPB</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>james.oconnor@manchester.ac.uk</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Boult</surname><given-names>JKR</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Jamin</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Babur</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Finegan</surname><given-names>KG</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Williams</surname><given-names>KJ</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Reynolds</surname><given-names>AR</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Little</surname><given-names>RA</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Jackson</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Parker</surname><given-names>GJM</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Waterton</surname><given-names>JC</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Robinson</surname><given-names>SP</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>University of Manchester, Oxford Road, Manchester, M13 9PL, UK</aff><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>2</day><month>10</month><year>2015</year></pub-date><volume>15</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the International Cancer Imaging Society (ICIS) 15th Annual Teaching Course</named-content><named-content content-type="supplement-sponsor">Publication charges for this supplement were funded through the International Cancer Imaging Society by support received from Siemens Healthcare GmbH.</named-content></supplement><fpage>P9</fpage><lpage>P9</lpage><permissions><copyright-statement>Copyright &#x000a9; 2015 O'Connor et al.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>O'Connor et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.cancerimagingjournal.com/content/15/S1/P9"/><conference><conf-date>5-7 October 2015</conf-date><conf-name>International Cancer Imaging Society Meeting and 15th Annual Teaching Course (ICIS 2015)</conf-name><conf-loc>London, UK</conf-loc></conference></article-meta></front><body><sec><title>Aim</title><p>There is need for non-invasive methods to identify, quantify and map tumour hypoxia. In this study we used an emerging technology &#x02013; R<sub>1</sub> oxygen enhanced MRI (OE-MRI) &#x02013; to distinguish those tumour sub-regions that respond to hyperoxic gas challenge from refractory sub-regions. We hypothesised that the proportion of refractory tumour tissue (Oxy-R) would be a robust biomarker of tumour hypoxia across multiple models with different vascular and hypoxic phenotypes.</p><p>Methods: OE-MRI signal precision, stability and relationship to tissue pO<sub>2</sub> were evaluated in well vascularised renal cancer 786-O xenografts. Dynamic sensitivity of proportional Oxy-R to acute changes in hypoxia was evaluated using hydralazine challenge. Relationship of proportional Oxy-R to tissue immunohistochemistry and gadolinium DCE-MRI were explored in parental and drug-resistant 786-O models and in SW620 xenografts.</p></sec><sec sec-type="results"><title>Results</title><p>Phantom and <italic>in vivo</italic> experiments demonstrated the accuracy, precision and stability of R<sub>1</sub> measurement. The proportion of tumour Oxy-R increased significantly following hydralazine challenge (p=0.045) relative to control. The proportion of tumour with perfused Oxy-R voxels was correlated to chronic hypoxia in well perfused 786-O-R xenografts(rho 0.810, p=0.028) and in relatively necrotic SW620 xenografts (rho 0.929, p=0.002).</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>The proportion of tumour perfused Oxy-R is a robust biomarker of tumour hypoxia. Voxel-wise analysis of dual oxygen and gadolinium challenge has potential to quantify and map tumour hypoxia as prognostic, predictive and pharmacodynamic biomarkers that could facilitate personalised healthcare.</p></sec></body></article>
